In conclusion, our study suggests that the YAP inhibitor verteporfin improves ISO-induced pathological cardiac hypertrophy, likely through the inhibition of the IL-6-STAT3 signaling pathway in CFs. Here, YAP1 is linked to cardiac hypertrophy.